In a previous study on high-grade serous ovarian cancer (HGSC), BRD1 expression was found to be low in tumor cells and high in immune cells, which is associated with significant downregulation of T cell- and NK cell-surface activity markers (GZMA, GZMB, IFNG, and NKG7) and upregulation of the naïve T cell marker TCF7 (73). This evidence concerns the gene IFNG and neoplasm.